Dynamics of MBT drug resistance in Saratov Region Hospital, Russia Source: International Congress 2016 – Epidemiological insights into tuberculosis pathogenesis Year: 2016
Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia) Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Dynamics of primary multidrug drug resistance in Novokuznetsk over 10 years period Source: International Congress 2016 – New insights into aspects of tuberculosis epidemiology Year: 2016
MDR TB treatment results of GFATM program implementation in Tomsk, Russia Source: International Congress 2015 – Management of TB: a patient focus Year: 2015
Risk factors for anti-TB drug resistance in Poland Source: Annual Congress 2013 –Tuberculosis: epidemiology and public health management III Year: 2013
Treatment outcomes and deaths among multidrug-resistant tuberculosis (MDR-TB) patients in Gomel region, Belarus – 2009-2010 Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013
Pattern of second line drug-resistance in MDR-TB treatment failure cases at a tertiary care tuberculosis treatment centre in western region of India Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Features of different M.tuberculosis strains that were isolated from MDR-TB patients in Kharkiv, Ukraine Source: International Congress 2016 – Epidemiological insights into tuberculosis pathogenesis Year: 2016
Trend and risk factors of drug resistance tuberculosis between 2005-2012 in Istanbul, Turkey Source: International Congress 2015 – Management of TB: a patient focus Year: 2015
Spreading of tuberculosis with extensive drug resistant MBTin Northwest region of Russia Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 1 Year: 2014
Tuberculosis and HIV infection in combination with multidrug resistant MBT on Northwest of Russia Source: International Congress 2016 – Epidemiological aspects of tuberculosis and other respiratory conditions: from lung cancer to late-onset Pompe's disease Year: 2016
Current status of fluoroquinolone use for treatment of tuberculosis in Korea Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Indicators of rifampicin-resistant TB response in Belarus, 2009-2014 Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Availability of PCR for second-line drugs in Europe Source: International Congress 2016 – Advances in tuberculosis diagnosis and monitoring of treatment Year: 2016
Active pharmacovigilance for multidrug-resistant tuberculosis patients treated with Linezolid, Belarus – 2014-2015 Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Prevalence of fluoroquinolon-resistance among different MDR tuberculosis cases in Ukraine Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013
Range of additional drug resistance of M.tuberculosis in XDR-TB patients Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Anti-tuberculosis drug resistance distinctive features -The Republic of Azerbaijan 2012-2013 Source: International Congress 2015 – Management of TB: a patient focus Year: 2015
Nationwide anti-tuberculosis drug resistance survey in the Republic of Azerbaijan Source: International Congress 2014 – Tuberculosis: epidemiology and public health Year: 2014
The top of the iceberg - Extensively drug resistant tuberculosis (XDR-TB) in 2010 Source: International Congress 2015 – Epidemiology of TB: deaths, co-morbidities, migration and children Year: 2015